|
|
Alex C. Spyropoulos, MD, FACP, FCCP
Medical Director, Clinical Thrombosis Center, Lovelace Medical Center
Alex C. Spyropoulos, MD received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in internal medicine. Dr. Spyropoulos is Founder and current Medical Director of the Clinical Thrombosis Center at Lovelace Health Systems in Albuquerque, New Mexico. As Clinical Associate Professor of Medicine and Associate Professor of Pharmacy at the University of New Mexico Health Sciences Center, he has developed a clinical thrombosis curriculum as part of the ambulatory medicine rotation. He is a Fellow of the American College of Physicians, American College of Chest Physicians, and International Academy of Clinical and Applied Thrombosis/Haemostasis. As a disease management consultant on anticoagulation in a managed care setting, Dr. Spyropoulos has been an integral member of Lovelace's Episode of Care disease management program on anticoagulation. He has helped to develop protocols using LMWH in outpatient-based treatment of venous thromboembolic disease, perioperative "bridging" for patients on chronic anticoagulation, post-operative DVT and medical inpatient prophylaxis, and protocols with regards to the use of direct thrombin inhibitors for HIT. Dr. Spyropoulos is active in assessing outcome analyses of these protocols, especially with regards to the implementation, safety, efficacy, and pharmacoeconomic indicators, and has lectured extensively both nationally and internationally on these issues. Dr. Spyropoulos' articles, letters, and editorials have been published in over 40 peer-reviewed journals including Chest, Journal of Thrombosis and Thrombolysis, Thrombosis Haemostasis, and Journal of Thrombosis Haemostasis.
|
|
|
|
|
Alan Wu, Ph.D., D.A.B.C.C.
Alan H.B. Wu, Ph.D., is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine, University of California, San Francisco. He received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. Dr. Wu’s research interest has been in three areas within the field of clinical chemistry laboratory. He has been involved at the national and international levels with development and use of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, and markers of myocardial ischemia, and stroke. As also has a long history of analytical, clinical, and forensic toxicology. In both of these areas, Dr. Wu has co-authored the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. More recently, Dr. Wu has developed research and clinical programs in pharmacogenomics in support of the UCSF clinical pharmacogenomics laboratory. Among the areas of interest include pharmacogenomics for anticoagulants, especially warfarin, chemotherapeutics (tamoxefin, irinotecan), and drugs that can induce hypersensitivity reactions (abacavir, anticonvulsants).
|
|
|
|
